Brief: Ventyx Biosciences Q3 EPS USD -0.32
06/11/2025 21:02
Nov 06 (Reuters) - Ventyx Biosciences Q3 operating expenses USD 24.874 million. Q3 net income USD -22.829 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions